Committed to innovation, we are dedicated to enhancing standard of care and improving patient lives. MediWound Ltd. Nasdaq: MDWD is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The Company specializes in the development, production and commercialization of rapid and effective biologics that improve existing standards of care and patient experiences, while reducing costs and unnecessary surgeries.
It has been designated as an orphan biologic drug. It is a concentrate of proteolytic enzymes enriched with bromelain for topical, easy to use daily applications. It demonstrated efficacy in debridement, the promotion of granulation tissue, and the reduction of bioburden and biofilm in various hard-to-heal wounds, effectively preparing the wound bed for healing. MW is an innovative topical biological drug currently in development to address the treatment needs of low-risk Basal Cell Carcinoma BCC.
MW is a promising therapy for low-risk Basal Cell Carcinoma. MediWound has extensive experience developing, manufacturing and commercializing biologics based on our core enzymatic technology. Nasdaq: MDWD , a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the third quarter ended September 30, , and provided a corporate update.
Nasdaq: MDWD , the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the third quarter ended September 30, , on Tuesday, November 26, ET at the H.
Wainwright 26th Annual Global Investment Conference. Nasdaq: MDWD , the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the U. Nasdaq: MDWD , the global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the second quarter ended June 30, , and provided a corporate update.
